BRAF and melanoma: To understand BRAFV600E inhibitor response in melanoma when generating BRAFV600E-inhibitor-resistant cell lines, we first compared the vemurafenib sensitivity of BRAFV600E mutation carrying the melanoma cells lines UACC62, A375, SK-MEL28, and M14 with BRAF WT carrying the melanoma cells lines MeWo and SK-Mel2.